GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Enlivex Therapeutics Ltd (XTAE:ENLV) » Definitions » E10

Enlivex Therapeutics (XTAE:ENLV) E10 : ₪-58.63 (As of Sep. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Enlivex Therapeutics E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Enlivex Therapeutics's adjusted earnings per share data for the three months ended in Sep. 2024 was ₪-0.428. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is ₪-58.63 for the trailing ten years ended in Sep. 2024.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2024-12-13), Enlivex Therapeutics's current stock price is ₪4.561. Enlivex Therapeutics's E10 for the quarter that ended in Sep. 2024 was ₪-58.63. Enlivex Therapeutics's Shiller PE Ratio of today is .


Enlivex Therapeutics E10 Historical Data

The historical data trend for Enlivex Therapeutics's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enlivex Therapeutics E10 Chart

Enlivex Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - -60.11 -62.50

Enlivex Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -68.52 -62.50 -60.67 -63.47 -58.63

Competitive Comparison of Enlivex Therapeutics's E10

For the Biotechnology subindustry, Enlivex Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Enlivex Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Enlivex Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Enlivex Therapeutics's Shiller PE Ratio falls into.



Enlivex Therapeutics E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Enlivex Therapeutics's adjusted earnings per share data for the three months ended in Sep. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=-0.428/133.0289*133.0289
=-0.428

Current CPI (Sep. 2024) = 133.0289.

Enlivex Therapeutics Quarterly Data

per share eps CPI Adj_EPS
201412 -31.402 99.070 -42.166
201503 -32.830 99.621 -43.839
201506 -37.112 100.684 -49.034
201509 -35.685 100.392 -47.286
201512 -48.531 99.792 -64.695
201603 -45.676 100.470 -60.478
201606 -31.402 101.688 -41.080
201609 -40.538 101.861 -52.942
201612 -27.120 101.863 -35.418
201703 -22.838 102.862 -29.536
201706 -14.274 103.349 -18.373
201709 -9.135 104.136 -11.670
201712 19.698 104.011 25.193
201803 -11.705 105.290 -14.789
201806 -9.706 106.317 -12.145
201809 -9.992 106.507 -12.480
201812 -13.449 105.998 -16.879
201903 -21.125 107.251 -26.203
201906 -3.997 108.070 -4.920
201909 -0.821 108.329 -1.008
201912 -0.999 108.420 -1.226
202003 -0.250 108.902 -0.305
202006 -0.821 108.767 -1.004
202009 -0.571 109.815 -0.692
202012 -1.534 109.897 -1.857
202103 -0.678 111.754 -0.807
202106 -0.607 114.631 -0.704
202109 -0.678 115.734 -0.779
202112 -0.963 117.630 -1.089
202203 -1.606 121.301 -1.761
202206 -1.927 125.017 -2.050
202209 -1.106 125.227 -1.175
202212 -1.392 125.222 -1.479
202303 -1.392 127.348 -1.454
202306 -1.320 128.729 -1.364
202309 -1.142 129.860 -1.170
202312 -1.713 129.419 -1.761
202403 -0.785 131.776 -0.792
202406 -0.571 132.554 -0.573
202409 -0.428 133.029 -0.428

Add all the adjusted EPS together and divide 10 will get our e10.


Enlivex Therapeutics  (XTAE:ENLV) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Enlivex Therapeutics E10 Related Terms

Thank you for viewing the detailed overview of Enlivex Therapeutics's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Enlivex Therapeutics Business Description

Traded in Other Exchanges
Address
14 Einstein Street, Ness Ziona, ISR, 7403618
Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.

Enlivex Therapeutics Headlines

From GuruFocus